Bristol submits hepatitis C drugs for FDA review

04/8/2014 | FDAnews

Bristol-Myers Squibb has filed new-drug applications with the FDA for approval to market its experimental drugs daclatasvir and asunaprevir as a treatment for hepatitis C genotype 1b. The combination regimen previously received breakthrough therapy status from the FDA.

View Full Article in:

FDAnews

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Counsel I – Clinical Contracts
Gilead Sciences
Foster City, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Vice President, Idaho Regional Director
PacificSource
Boise, ID